Alzheimers Dement. 2024 Feb 8. doi: 10.1002/alz.13726. Online ahead of print.

ABSTRACT

INTRODUCTION: Trialists need a thorough understanding of whether reactions to Alzheimer’s disease (AD) biomarker information differ among racial and ethnic groups in preclinical AD trials.

METHODS: We used data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Study to analyze cognitively unimpaired participants’ responses on the Impact of Event Scale (IES) 24 to 72 hours after amyloid disclosure. We fit a linear regression model to test whether mean IES scores differed among participants from specific racial and ethnic groups. We considered potential effect modification by amyloid status.

RESULTS: Reactions to disclosure did not significantly differ among participant groups based on self-reported race and ethnicity. Although the results were not significant when stratified by amyloid status, all racial and ethnic groups except for participants self-reporting Hispanic/Latino ethnicity were observed to have higher mean IES in the elevated amyloid group.

DISCUSSION: These results support continued use of current disclosure methods in preclinical AD trials.

PMID:38329007 | DOI:10.1002/alz.13726